and C were among the important public health issues examined at the
recent annual meeting of the American Public Health Association (APHA)
Exit Disclaimer. The annual meeting, held November 14-19, 2014 in New
Orleans, Louisiana, is one of the nation's largest gatherings of public
health professionals, including clinicians, researchers, policy makers,
students, and others committed to public health.'
'A new report
found that prescriptions for ledipasvir and sofosbuvir, the newest
hepatitis C treatment, are growing rapidly but the minimal reduction in
sofosbuvir prescriptions indicates an overall expansion of the eligible
treatment population rather than the former drug replacing the latter,
according to a press release.'
'2014 has been
a year of both opportunities and challenges in the fight against viral
hepatitis. In May, the World Health Assembly passed a new resolution
Exit Disclaimer [PDF 151 KB] on viral hepatitis, urging member states
to develop and implement coordinated, national strategies for
preventing, diagnosing and treating viral hepatitis.'
Sciences (NASDAQ: GILD ) got all the press last year thanks
to its hepatitis C drugs Sovaldi and Harvoni, but despite its 27%
return in 2014, Gilead Sciences wasn't the best-performing hepatitis C
drug stock this past year. Small-cap biotechnology stock Regulus
Therapeutics (NASDAQ: RGLS ) put up far more impressive
returns, gaining 117%. Since this small-cap biotech stock more than
doubled investor's money in 2014, let's learn more about it.'
and ribavirin treatments should be administered to patients with
hepatitis C virus who undergo liver transplantations in order to
significantly decrease the risks of posttransplant HCV recurrence,
according to two new studies published in the January issue of
Gastroenterology (10.1053/j.gastro.2014.09.023 and